News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Japan Patent For Cyclosporin Brain-Protection Granted To Maas BiolAB


10/19/2005 5:09:57 PM

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--May 19, 2005--Maas BiolAB, LLC announced that the Japan Patent Office has granted patent number 3643380. The Maas Japan patent is for Cyclosporin Neuroprotection treating the gamut of neurological diseases. Cyclosporin has been shown to be a powerful and effective neuroprotectant in preclinical models of neurological diseases from traumatic brain injury to amyotrophic lateral sclerosis (ALS). Japan, with a population of 127 million people, is the second largest pharmaceutical market in the world. Maas BiolAB has been granted patents in 36 countries including North America (USA, Canada, Mexico), Europe (Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Ireland, Italy, Latvia, Lithuania, Luxembourg, Monaco, Netherlands, Portugal, Slovenia, Spain, Sweden, Switzerland, United Kingdom), Africa (Ghana, Kenya, Lesotho, Malawi, Sudan, Swaziland, Uganda, Zimbabwe), Antipodes (Australia, New Zealand), Russia, China, and now Japan.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES